The Best Colorectal Cancer Screening Test Is the One You'll Actually Do

A common patient question is, "Which test is the best one?"

It doesn't have a simple answer. But it has a real one. And getting it right starts with understanding what each test actually measures — because not all of them are doing the same thing.

This Is No Longer Just an Older Adult's Disease

Colorectal cancer has long been framed as a disease of aging. That framing is no longer accurate.

A January 2026 study published in JAMA — analyzing nearly 1.3 million cancer deaths in adults under 50 over three decades — found that colorectal cancer is now the leading cause of cancer death in Americans under 50. In 1990 it ranked fifth. It claimed the top spot in 2023, seven years ahead of projections.

Here's what makes that finding stark: overall cancer death rates in people under 50 have dropped 44 percent since 1990. Every other major cancer — breast, lung, brain, leukemia — has declined in this age group. Colorectal cancer is the only one moving in the wrong direction, with mortality rising approximately 1 percent per year since 2005.

Today, 1 in 5 colorectal cancer diagnoses occurs in someone under 55 — double the rate from 1995. And about three in four of those younger patients are diagnosed with advanced disease. Not because the cancer is more aggressive in young people, but because no one was looking for it.

Colorectal cancer is now the #1 cause of cancer death in adults under 50. It reached that milestone seven years ahead of schedule — not because the disease changed, but because we weren't screening early enough.

Detection vs. Prevention — Why the Distinction Matters

There's a difference that gets lost in these conversations: early detection is not the same as prevention.

Early detection means finding cancer after it has formed — ideally before it has spread.

Prevention means identifying and removing pre-cancerous lesions before they ever become cancer. Both have value. They are not the same thing.

Most screening tests do one or the other. Only one does both.

What Each Test Actually Does

Stool-Based Tests

FIT (fecal immunochemical test) detects hidden blood in the stool. Done at home, no dietary restrictions, recommended annually. Sensitive for established cancer but only detects a minority of large adenomas — typically well under half — because polyps don’t bleed reliably enough. A positive result requires follow-up colonoscopy.

Stool DNA testing (Cologuard) combines FIT with analysis of DNA shed by abnormal colon cells. More sensitive for cancer than FIT alone, but with a higher false-positive rate. Recommended every one to three years. A positive result also routes to colonoscopy.

gFOBT (guaiac-based fecal occult blood test) uses a guaiac reaction, requires dietary restrictions, is done annually, and has been largely replaced by FIT in practice while still appearing in some guideline documents.

Stool RNA testing (ColoSense, from Geneoscopy) is the newest stool-based option. It analyzes RNA biomarkers plus a FIT component and was FDA-approved in 2024 for average-risk adults 45 and older. Early data show high sensitivity for cancer and moderate sensitivity for advanced polyps, but real-world and long-term comparative data are still emerging, and recommended intervals will likely settle around an every-3-year cadence.

Blood-Based Tests

Shield (Guardant Health) analyzes cell-free DNA in the bloodstream for cancer-associated changes. FDA-approved in 2024, recommended every three years. Better at detecting established cancer than pre-cancerous lesions. Positive result requires colonoscopy. Lowest barrier of any option — a standard blood draw.

Septin 9 (Epi proColon) detects methylated SEPT9 DNA in plasma. FDA-approved specifically for patients who are unwilling or unable to undergo standard screening. Lower sensitivity than other options and not a first-line recommendation, but it extends access to patients who would otherwise go unscreened.

Structural Tests

CT colonography can visualize polyps but cannot remove them. Any significant finding requires a second procedure. It has a role — but it adds a step rather than completing the work.

Flexible sigmoidoscopy examines only the left side of the colon. It misses 30 to 50 percent of proximal lesions. For a disease increasingly presenting in younger patients and in the right colon, that's a meaningful coverage gap.

Colonoscopy: Why I Consider It the Gold Standard

Colonoscopy examines the entire colon. When a polyp is found, it's removed in the same session. No second appointment, no follow-up procedure — the diagnosis and the intervention happen together.

That capability is what separates it from everything else. And it's the basis of where I stand clinically: I believe colonoscopy remains the gold standard for colorectal cancer screening, because it's the only tool that offers both detection and prevention in a single encounter.

I would rather see you with a pre-cancerous polyp than with a cancer. That's not a philosophical preference — it's a practical one. Removing an adenoma during a routine procedure is a different conversation than discussing staging, surgery, chemotherapy, and survival odds.

Adenomas don't cause symptoms. They don't bleed consistently enough for stool or blood tests to catch them reliably. They sit quietly and, over years, some become cancer. Colonoscopy finds them at that stage and removes them. That is prevention.

Prevention is not the same as early detection. Colonoscopy is the only screening test that does both — and I would rather see you with a polyp than a cancer.

What Patients Get Wrong About Colonoscopy

The most common reason people delay colonoscopy isn't the procedure — it's assumptions about it that turn out not to be true.

• The prep is not what it used to be. The gallon-jug preparation is largely gone. Most patients now use low-volume, split-dose regimens taken in two smaller sessions. It's not comfortable, but it is consistently described as easier than anticipated.

• There is no pain. Colonoscopy is performed under sedation. Most patients have no memory of it. They go to sleep and wake up in recovery.

• The time commitment is a half morning, not a lost day. Check-in, the procedure (typically 20 to 40 minutes), and a brief recovery period. The only hard requirement is a driver.

• A normal might result in up to ten years of coverage. One procedure, one morning, a decade of protection for average-risk patients. When patients hear that, the calculus sometimes shifts.

Back to Her Question

I told that patient what I tell everyone: the best test is the one you'll complete.

For her — 47 years old, family history of CRC, no prior screening — we talked through her options and she chose colonoscopy. Not because it's the right answer for everyone. Because it was the right answer for her, once she understood what she was trying to accomplish.

If you're 45 or older and haven't been screened, make the call this month. If you're under 45 with a family history, talk to your physician about whether earlier screening is appropriate. The data are clear. This disease is preventable. And we now know it doesn't wait until you're older.

---

Read more about Colorectal Cancer Awareness Month.